BackBig Pharma Split Overview

Big Pharma Split Receivables

Latest receivables for PRM.TO: $120K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$117080.00
↑ 16.15% YoYΔ $16281.00 vs prior year quarter

Peer trimmed avg / median

Loading

Big Pharma Split Receivables History

Loading

Big Pharma Split vs. peers: Receivables Comparison

Loading

Big Pharma Split Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Big Pharma Split (PRM.TO) FAQ

As of the most recent data (June 2026), PRM.TO shows a receivables of $120K. That compares with $100K in the prior-year period — up 16.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PRM.TO's receivables is now $120K (was $100K) — a 16.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Big Pharma Split is outperforming or lagging.

Tracking PRM.TO's receivables over time shows whether Big Pharma Split is scaling, shrinking, or reshaping that part of the business. The current reading is $120K That compares with $100K in the prior-year period — up 16.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Big Pharma Split's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $120K) with ownership activity and broader fundamentals.